ITM Appoints Dr. Danielle Meyrick as Chief Medical Officer
May 07 2024 - 5:00AM
- Leveraging profound knowledge in radiopharmaceutical drug
development and commercial planning, Dr. Meyrick will lead the
medical team in further developing and delivering on ITM's pipeline
strategy
- After a career spanning more than 45 years, Dr. Philip E.
Harris will retire
Garching / Munich, Germany, May 7, 2024 –
ITM Isotope Technologies Munich SE (ITM), a leading
radiopharmaceutical biotech company, today announced the
appointment of Danielle Meyrick, PhD, MD, as Chief Medical Officer.
Dr. Meyrick brings more than 20 years of medical research,
radiotheranostic drug development and management experience to ITM.
She has held senior leadership roles across international biotech
and radiopharmaceutical organizations including GenesisCare,
AdvanCell Isotopes and Telix Pharmaceuticals. Dr. Meyrick will lead
ITM’s medical team in expanding and advancing the company’s
radiopharmaceutical pipeline while overseeing the last stages of
clinical development and commercial readiness for phase III lead
candidate, ITM-11. She replaces Dr. Philip E. Harris, ITM’s CMO
from 2018, who is retiring from the company.
“Danielle’s successful track record of advancing
theranostic drug candidates through the clinic, coupled with her
deep understanding of the industry will be a real advantage in the
continued build out of our robust radiopharmaceutical pipeline. Her
patient-centric approach and commitment to advancing innovation in
nuclear medicine align with our mission as an organization. I
welcome Danielle to the team. At the same time, I want to thank
Philip for his commitment and leadership over the past six years
which have left a lasting positive impact on our company’s
trajectory,” said Steffen Schuster, CEO of ITM.
Dr. Meyrick has held various executive positions
in the biotechnology and radiopharmaceutical field. Before joining
ITM, Dr. Meyrick was Chief Scientific Officer, Research and
Insights at GenesisCare where she spearheaded medical and clinical
strategies with a focus on radiopharmaceutical development. Dr.
Meyrick also served as the consulting Chief Medical Officer at
AdvanCell Isotopes where she led clinical development efforts
across pipeline assets. As Chief Medical Officer, APAC and Global
Head of Clinical Science at Telix Pharmaceuticals, Dr. Meyrick
oversaw the clinical development of theranostic radiopharmaceutical
candidates in the Asia Pacific region and supported commercial
strategic planning efforts.
"My career in the radiopharmaceutical sector has
always been driven by a desire to provide improved care and
outcomes for patients living with cancer and I believe that ITM is
at an exciting juncture to deliver on this goal. The company has
the unique ability to apply its expertise in high-quality
radioisotope manufacturing to its own radiopharmaceutical drug
candidates. I look forward to working with the team to build
our pipeline with a variety of drug candidates and radioisotopes
and bring ITM-11 across the finish line,” said Danielle Meyrick,
CMO of ITM.
Dr. Meyrick’s early career was shaped by various
scientific and medical residences at hospitals in the U.S. and
Australia, including at the Department of Nuclear Medicine at
Fremantle Hospital in Western Australia. She holds a PhD in
Physical Chemistry and Radiopharmaceutical Chemistry from Murdoch
University, and a Doctor of Medicine, awarded by the University of
Western Australia. Dr. Meyrick has been published in more than 60
scientific journals and conference papers.
About ITM Isotope Technologies Munich
SE
ITM, a leading radiopharmaceutical biotech
company, is dedicated to providing a new generation of
radiomolecular precision therapeutics and diagnostics for
hard-to-treat tumors. We aim to meet the needs of cancer patients,
clinicians and our partners through excellence in development,
production and global supply. With improved patient benefit as the
driving principle for all we do, ITM advances a broad precision
oncology pipeline, including two phase III studies, combining the
company’s high-quality radioisotopes with a range of targeting
molecules. By leveraging our nearly two decades of pioneering
radiopharma expertise, central industry position and established
global network, ITM strives to provide patients with more effective
targeted treatment to improve clinical outcome and quality of life.
www.itm-radiopharma.com
ITM ContactCorporate CommunicationsKathleen Noonan
/ Julia WestermeirPhone: +49 89 329 8986
1502Email: communications@itm-radiopharma.com
Investor RelationsBen OrzelekPhone: +49 89 329 8986
1009Email: investors@itm-radiopharma.com
- 07052024_ITM Announcement_CMO Danielle Meyrick
- ITM Announcement_Portrait Photo Dr. Danielle Meyrick